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Clinical manifestations of lower extremity peripheral
arterial disease (PAD) are associated with decrements
in functional capacity and quality of life, cause limb
amputation and increase risk of death (1,2). The sys-
temic nature of the atherosclerotic process also con-
tributes to the development of concomitant disease
of the arteries to the heart and brain, hence to an
associated increased risk of cardiovascular ischaemic
events, such as myocardial infarction, ischaemic
stroke and cardiovascular death. Even, vascular mor-
bidity and mortality are similar in patients with
symptomatic or asymptomatic PAD (3). Individuals
with asymptomatic PAD should be identiﬁed so that
therapeutic interventions known to diminish their
increased risk of ischaemic events may be offered
(1). Early diagnosis and treatment of PAD are
increasingly recognised as a health burden worldwide
(4).
The ankle-brachial index (ABI) is a measurement
that provides objective data for the diagnosis of
PAD. The overall accuracy of the ABI to establish
PAD diagnosis has been well-established against con-
trast angiography and Doppler ultrasound (5–8) and
is considered to have good reproducibility (9–12). It
is usually obtained by measuring the resting systolic
blood pressure (SBP) from the brachial, dorsalis
pedis and posterior tibial arteries; dividing in each
leg, the highest of the ankle pressures by the highest
of the brachial pressures; then taking the lowest
result (13,14). Besides, it is the recommended stan-
dard for PAD diagnosis; a low ABI is consistently
associated with increased mortality and risk of
SUMMARY
Aims:The deleterious nature of peripheral arterial disease (PAD) is compounded by
a status of underdiagnosed and undertreated disease. We evaluated the prevalence
and predictive factors of PAD in high-risk patients using the ankle-brachial index
(ABI). Methods:The ABI was measured by general practitioners in France (May
2005–February 2006) in 5679 adults aged 55 years or older and considered at
high risk. The primary outcome was prevalence of PAD (ABI strictly below 0.90).
Results:In all, 21.3% patients had signs or symptoms suggestive of PAD, 42.1%
had previous history of atherothrombotic disease and 36.6% had two or more car-
diovascular risk factors. Prevalence of PAD was 27.8% overall, ranging from
10.4% in patients with cardiovascular risk factors only to approximately 38% in
each other subgroup. Prevalence differed depending on the localization of athero-
thrombotic events: it was 57.1–75.0% in patients with past history of symptomatic
PAD; 24.6–31.1% in those who had experienced cerebrovascular and⁄or coronary
events. Regarding the classical cardiovascular risk factors, PAD was more frequent
when smoking and hypercholesterolemia history were reported. PAD prevalence
was also higher in patients with history of abdominal aortic aneurysm, renal hyper-
tension or atherothrombotic event. Intermittent claudication, lack of one pulse in
the lower limbs, smoking, diabetes and renovascular hypertension were the main
factors predictive of low ABI. Conclusions:Given the elevated prevalence of PAD
in high-risk patients and easiness of diagnosis using ABI in primary care, undoubt-
edly better awareness would help preserve individual cardiovascular health and
achieve public health goals.
What’s known
Peripheral arterial disease (PAD) is an
atherothrombotic syndrome associated with
elevated risk of cardiovascular and cerebrovascular
events. Its deleterious nature is compounded by a
status of underdiagnosed and undertreated disease.
Ankle-brachial index (ABI) measurement easily
provides reliable data for diagnosis of PAD. In
practice, however, diagnosis is still usually based
on the presence of symptoms.
What’s new
The ABI was measured in 5679 high-risk patients
by general practitioners in France. Prevalence of
PAD was high (28%) and ranged from 10% in
patients with cardiovascular risk factors only to
38% in other (symptomatic or not) high-risk
patients. Factors predictive of low ABI were
identiﬁed. Better awareness of such elevated
prevalence would help preserve individual health
and achieve public health goals.
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doi: 10.1111/j.1742-1241.2008.01953.x 63cardiovascular disease (2). Early detection of PAD
using ABI at least in patients considered at high risk
should allow preventive intervention taking place
earlier and improve cardiovascular outcome. How-
ever, although easily assessable, the ABI is largely
underused in ofﬁce practice and the deleterious
nature of PAD is compounded by a status of under-
diagnosed and undertreated disease (15).
Knowledge of the epidemiology of PAD arises
from prevalence studies carried out in the USA or in
various European countries, based on the presence of
intermittent claudication for the oldest studies
(16,17) or on the ABI measurement for the most
recent evaluations (18–22). The only prevalence
study in France was performed 10 years ago (23).
We present the results of a recent, large study carried
out in France to evaluate the prevalence and predic-
tive factors of PAD using the ABI in general practice,
in patients considered at high risk.
Methods
General practitioners in France, randomly selected
from a national database, were proposed to partici-
pate in this cross-sectional study. Those who agreed
to participate received a speciﬁc training to perform
ABI measurements under standardised condition.
Training was carried out by experienced angiologists
and cardiologists during study workshops.
The ﬁrst ﬁve consecutive patients aged 55 years or
older were recruited if they were considered at high
risk for PAD, irrespective of the reason for seeing the
doctor. Three clinical, mutually exclusive, subgroups
at high risk were predeﬁned (17,18,20,24–26) as fol-
lows. Group 1 – One or more signs or symptoms
suggestive of PAD: ﬁrst evidence of intermittent
claudication; atypical pain in a leg muscle (calf, thigh
or buttock) while walking; pulseless lower limb artery
(dorsalis pedis, posterior tibial, popliteal or femoral);
iliac or femoral bruits and⁄or lower limb ulcer or
gangrene. Group 2 – History of one or more athero-
thrombotic events (secondary prevention): myocar-
dial infarction (Q wave or non-Q wave); angina
pectoris (stable or unstable); stroke or ischaemic
attack; previously established symptomatic PAD (Ler-
iche-Fontaine stage II or higher) and⁄or carotid, cor-
onary or lower limb artery revascularization (bypass
graft or angioplasty). Group 3 – Two or more car-
diovascular risk factors only without history of ath-
erothrombotic event (primary prevention): history of
smoking, hypercholesterolemia, diabetes and⁄or
hypertension.
Patients’ demographic characteristics, body weight
and height, signs or symptoms suggestive of PAD,
cardiovascular medical and surgical history were
searched by physical examination, by questioning
and from the medical record. Smoking history was
established in patients currently or formerly smoking
at least one cigarette per day. Hypercholesterolemia
was deﬁned as a fasting low-density lipoprotein (LDL)
cholesterol concentration of 1.3 g⁄l (3.4 mmol⁄l) or
more on two occasions within the past year. The most
recent concentrations of total, LDL and high-density
lipoprotein (HDL) cholesterol were also retrieved.
Diabetes was deﬁned, regardless of whether it was
type 1 or type 2, as a fasting glycaemia of 1.26 g⁄lo r
more on two occasions and⁄or use of diabetes medi-
cation. Arterial hypertension was diagnosed as a SBP
of 140 mmHg or more, a diastolic blood pressure of
90 mmHg or more on two occasions and⁄or use of
treatment.
Outcome measures
The primary outcome measure was the ABI. Mea-
surements were performed under standardised condi-
tion by the general practitioners. A Doppler
ultrasonic pen device (8 mHz, Mini Dopplex
 
D900⁄EZ8; Huntleigh Healthcare Inc., Eatontown,
NJ) was used with a standard sphygmomanometer at
each site. With each subject in supine position and
after a 5-minute rest, SBP was recorded in the right
upper extremity at the brachial artery and in both
lower extremities at the posterior tibial and dorsalis
pedis arteries. We choose deliberately the most sensi-
tive method for calculating the ABI. General practi-
tioners calculated the ABI by dividing the lowest of
the four ankle systolic pressures by the brachial sys-
tolic pressure.
Sample size and statistical analysis
The primary outcome was the prevalence of PAD as
deﬁned by an ABI strictly below 0.90, which is
known to vary between 5 and 80% depending on the
risk proﬁle and the threshold ABI chosen (23).
Assuming that the smallest subgroup of interest
would represent approximately 7% of the cohort, we
determined that a sample of 8571 (600⁄0.07) patients
was required to observe a prevalence of 10–50% with
a precision of ± 2.5–4.0%.
Standard descriptive statistics were provided for all
variables; 95% conﬁdence intervals (CIs) were calcu-
lated when appropriate. Proportions were calculated
taking into account missing data in the denominator.
Groups were compared using the v
2 test. Factors
predictive of PAD were investigated by multivariate
logistic regression with backward elimination (at the
0.20 level) in the population of patients without pre-
viously established symptomatic PAD, regardless of
the univariate analyses results. The following vari-
ables were entered in the initial model: patients’
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toms suggestive of PAD); traditional cardiovascular
risk factors (hypertension, hypercholesterolemia, dia-
betes, smoking status, brachial SBP at the visit and
latest measurement of LDL cholesterol); history of
atherothrombotic events [abdominal aortic aneu-
rysm, renovascular hypertension (renal artery steno-
sis), angina pectoris or myocardial infarction or
coronary artery angioplasty⁄bypass graft, stroke, car-
otid artery angioplasty⁄bypass graft]. The corres-
ponding odds ratios and their 95% CI were
calculated. Statistical signiﬁcance was accepted at the
two-sided 0.05 level. Data were analysed using sas
 
8.02 (SAS Institute Inc., Cary, NC).
Results
Patients’ characteristics
Between 2 May 2005 and 15 February 2006, 1219
general practitioners well-distributed throughout the
nation included 5679 consecutive patients aged 55 or
above, who they considered were at high risk for
PAD. Of these, 1209 (21.3%) patients belonged to
group 1; 2393 (42.1%) to group 2; 2077 (36.6%) to
group 3. Table 1 summarises patient characteristics
in the overall cohort and in these predeﬁned sub-
groups.
Patients considered at high risk were mainly men
(63.3%) with hypertension (80.9%) and⁄or hyper-
cholesterolemia (74.0%); 22.8% had a smoking his-
tory. In group 1, 60.7% of patients had leg pain
while walking; it was intermittent claudication in less
than half of the patients. A majority of patients in
group 2 had history of coronary artery disease
(angina pectoris 53.2% and⁄or myocardial infarction
31.8%). The cardiovascular risk factors most fre-
quently reported in group 3 were hypertension
(89.6%), hypercholesterolemia (80.0%) and to a
lower extent diabetes (42.9%). Distribution of risk
factors was roughly similar in all subgroups.
History of PAD (without lower limb revasculariza-
tion and⁄or amputation) was recorded in 302
patients overall. Among them, 212 (70.2%) had
intermittent claudication, 205 (73.2%) had at least














Mean (SD) age, year 69.1 (8.7) 68.8 (8.8) 71.0 (8.9) 67.2 (8.0)
Males 3593 (63.3) 699 (57.8) 1755 (73.3) 1139 (54.8)
Mean (SD) body mass index, kg⁄m
2 27.6 (4.6) 27.6 (4.8) 27.1 (4.3) 28.2 (4.7)
Leg pain while walking 1975 (34.8) 734 (60.7) 995 (41.6) 246 (11.8)
Intermittent claudication 864 (15.2) 305 (25.2) 559 (23.3) 0 (0)
Pulseless dorsalis pedis and⁄or posterior tibial artery 1596 (28.1) 770 (63.7) 826 (34.5) 0 (0)
Cardiovascular history
Angina pectoris 1274 (22.4) 0 (0) 1274 (53.2) 0 (0)
Myocardial infarction 762 (13.4) 0 (0) 762 (31.8) 0 (0)
Ischaemic stroke 365 (6.4) 0 (0) 365 (15.3) 0 (0)
Previously established symptomatic PAD 554 (9.8) 0 (0) 554 (23.2) 0 (0)
Symptomatic heart failure 385 (6.8) 58 (4.8) 290 (12.1) 37 (1.8)
Lower limb artery bypass graft or angioplasty 312 (5.5) 0 (0) 312 (13.0) 0 (0)
Coronary artery bypass graft or angioplasty 876 (15.4) 0 (0) 876 (36.6) 0 (0)
Carotid bypass graft or angioplasty 186 (3.3) 0 (0) 186 (7.8) 0 (0)
Abdominal aortic aneurysm 133 (2.3) 14 (1.2) 101 (4.2) 18 (0.9)
Renovascular hypertension (renal artery stenosis) 89 (1.6) 10 (0.8) 67 (2.8) 12 (0.6)
Lower limb amputation 20 (0.4) 0 (0) 20 (0.8) 0 (0)
Cardiovascular risk factors
Hypertension 4593 (80.9) 907 (75.0) 1824 (76.2) 1862 (89.6)
Hypercholesterolemia 4201 (74.0) 777 (64.3) 1762 (73.6) 1662 (80.0)
Diabetes 2056 (36.2) 437 (36.1) 729 (30.5) 890 (42.9)
Smoking 1292 (22.8) 334 (27.6) 470 (19.7) 488 (23.5)
None 205 (3.6) 59 (4.6) 146 (6.1) 0 (0)
Two or more 4711 (83.0) 898 (74.3) 1736 (72.5) 2077 (100)
PAD, peripheral arterial disease.
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a pulseless dorsalis pedis and⁄or posterior tibial
artery.
Prevalence of PAD in the cohort (univariate
analyses)
Prevalence of PAD was 27.8% (95% CI: 26.6–28.9)
in the overall cohort (Figure 1). The ABI was below
0.50 in 1.0% of patients only. Mean duration of ABI
measurement was 11.5 ± 6.06 min (median 10.0).
Univariate analyses (Table 2) showed increased
prevalence of PAD in men, patients with older age
or patients with history of coronary artery disease.
PAD was approximately three times more frequent
when at least one dorsalis pedis or tibial artery pulse
was absent, or intermittent claudication was present,
compared with when these symptoms were absent.
To a lesser extent, prevalence of PAD was enhanced
when brachial SBP was 160 mmHg or above at the
visit, patients had a smoking history, history of
hypercholesterolemia was absent, or recent HDL cho-
lesterol levels were below 1 mmol⁄l (p < 0.001).
PAD was also more frequent in patients with history
of renal hypertension (52.8 vs. 27.4%, p < 0.0001) or
abdominal aortic aneurysm (36.8 vs. 27.5%,
p < 0.05). There was no signiﬁcant impact of history
of hypertension, history of diabetes or recent LDL
cholesterol levels.
Prevalence of PAD in the predeﬁned clinical
subgroups (univariate analyses)
The subgroups signiﬁcantly differed for the preva-
lence of PAD (p < 0.0001, Figure 1). PAD affected
37.4% (95% CI: 34.7–40.2) of patients in group 1
and 38.0% (95% CI: 36.0–40.0) of patients in group
2, whereas prevalence of PAD was the lowest (10.4%,
95% CI: 9.1–11.7) in patients with two or more car-
diovascular risk factors only.
In each subgroup as in the whole cohort (Table 2),
prevalence of PAD was increased in univariate analy-
sis in patients with symptoms of PAD, smoking his-
tory, increased number of cardiovascular risk factors
or excessive brachial SBP at the visit.
In group 2, prevalence of PAD was the highest in
patients with past history of symptomatic PAD; the
lowest in patients who had experienced cerebrovas-
cular and⁄or coronary events only (p < 0.0001, Fig-
ure 2). In particular, it was 70.7% in those with
previous symptomatic PAD and no other vascular
localization, whereas it was 26.6% in patients with
history of coronary events and no other vascular his-
tory and 24.6% in those with history of isolated cere-
brovascular events. Prevalence of PAD was increased
in patients with history of atherothrombotic events.
PAD was also more frequent in patients with history
of renovascular hypertension (58.2 vs. 37.4%,
p < 0.001).
In group 3, increased prevalence of PAD was
observed with smoking habits, excessive brachial SBP
at the visit or a history of renovascular hypertension
(33.3 vs. 10.3%, p < 0.01). No relationship was
found using univariate analyses between an ABI
below 0.9 and diabetes, hypertension or the number
of cardiovascular risk factors.
Factors predictive of PAD (multivariate
analyses)
The independent variables signiﬁcantly associated
with diagnosis of PAD using the ABI are displayed
in Table 3. The statistical model retained the follow-
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Figure 1 Prevalence of peripheral arterial disease (ankle-brachial index < 0.90) in the cohort (n = 5679) and in the
predeﬁned clinical subgroups
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symptom suggestive of PAD, cardiovascular risk fac-
tors (smoking, diabetes and elevated LDL choles-
terol), history of renovascular hypertension and
coronary artery disease.
Discussion
Peripheral arterial disease in high-risk patients of
55 years or more was highly prevalent (27.8%) and
easily detected by a simple ABI measurement in
Table 2 Prevalence of peripheral arterial disease (ankle-brachial index < 0.9) according to patient characteristics, in the cohort and in predeﬁned
clinical subgroups. Univariate analysis
Characteristic






disease (n = 2393)
3. Cardiovascular risk
factors only (n = 2077)
Prevalence (%) p-value Prevalence (%) p-value Prevalence (%) p-value Prevalence (%) p-value
Demography
Gender Male 30.2 < 0.0001 37.5 ns 40.4 < 0.0001 10.1 ns
Female 23.5 37.3 31.3 10.7
Age (year) (55–64) 24.3 < 0.0001 37.7 ns 35.6 ns 9.4 ns
(64–74) 27.1 36.2 38.9 10.3
‡ 74 31.6 38.3 38.6 12.1
Vascular history
Coronary artery disease Yes 33.0 < 0.0001 na na 33.0 < 0.0001 na na
No 25.5 50.4
Ischaemic stroke Yes 27.7 ns na na 27.7 < 0.0001 na na
No 27.8 39.8
Signs⁄Symptoms of PAD
Intermittent claudication Yes 65.9 < 0.0001 52.1 < 0.0001 73.3 < 0.0001 na na
No 20.9 32.4 27.2
Pulseless dorsalis pedis artery Yes 57.5 < 0.0001 46.2 < 0.0001 66.8 < 0.0001 na na
No 19.4 30.1 26.3
Pulseless posterior tibial artery Yes 56.0 < 0.0001 43.8 < 0.001 66.5 < 0.0001 na na
No 21.6 33.3 29.6
Modiﬁable cardiovascular risk factors
History of hypertension Yes 27.2 ns 37.3 ns 39.4 < 0.05 10.4 ns
No 30.0 37.7 33.6 9.8
History of hypercholesterolemia Yes 26.9 < 0.05 38.9 ns 38.1 ns 9.3 < 0.01
No 30.2 34.7 37.6 14.5
Smoking Current 37.4 < 0.0001 49.1 < 0.0001 54.6 < 0.0001 14.3 < 0.01
Cessation £ 1 year 40.5 57.6 50.5 14.6
Cessation > 1 year 33.3 37.3 42.0 10.4
No 21.2 30.5 29.5 8.8
Diabetes Yes 28.6 ns 38.2 ns 44.2 < 0.0001 11.0 ns
No 27.3 36.9 35.3 9.9
Number of risk factors 4 45.7 < 0.0001 68.9 < 0.0001 54.2 < 0.0001 18.8 ns
3 30.8 38.2 47.7 10.0
2 23.6 37.7 34.6 10.1
1 33.6 33.7 33.5 0.0
0 25.4 22.0 26.7 0.0
Measurements at the visit
SBP (mmHg) < 140 25.4 < 0.0001 34.8 < 0.01 33.2 < 0.0001 9.5 < 0.01
[140–160] 26.4 35.6 38.5 9.1
‡ 160 37.2 47.1 50.5 15.9
LDL cholesterol (mmol⁄l) < 2.6 26.4 ns 34.0 ns 34.7 < 0.01 8.9 ns
(2.6–3.3) 25.0 36.4 33.8 8.1
(3.3–4) 27.7 35.7 41.8 12.0
‡ 4 29.5 42.9 45.6 9.2
na, not applicable; ns, not signiﬁcant; SBP, systolic blood pressure; LDL, low-density lipoprotein; PAD, peripheral arterial disease.
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ing out of lack of one pulse in the lower limbs,
smoking, diabetes and renovascular hypertension
(renal artery stenosis) were the main factors predic-
tive of low ABI. On the basis of these results, we rec-
ommend to screen for low ABI, in the primary care
setting, at least patients presenting with these factors.
Prevalence of PAD ranged from 10.4% in patients
with high-risk cardiovascular proﬁle only, to approx-
imately 38% in patients with symptoms suggestive of
PAD and more than 25% in patients with previous
history of cerebrovascular or coronary disease. Low
ABI (below 0.75) was observed in < 3% of patients
with multiple risk factors only, but in 17–20% in the
other subgroups. It may be noted that PAD was
diagnosed in only 46.2–68.8% of patients with a
pulseless dorsalis pedis or posterior tibial artery. This
underlines the uncertainty of such clinical examina-
tion and the necessity of Doppler ultrasound exami-
nation.
Prevalence differed depending on localization of
previous atherothrombotic events. It was already
high (24.6–31.1%) in patients who had experienced
cerebrovascular and⁄or coronary events. It was much
higher in patients with past history of symptomatic
PAD (57.1–75.0%), but not as high, however, as one
would have expected. This was probably because
70.8% of patients with previously established PAD
and an ABI of 0.9 or above had undergone a revas-
cularization procedure and some patients were diag-
nosed in the past based on clinical examination only.
Similar results were obtained in the Agatha study
(27).
Moreover, not all cardiovascular risk factors inﬂu-
enced the presence of PAD. PAD was more frequent
in patients with smoking habits or diabetes and, to a
lower extent, in those with history of abdominal aor-
tic aneurysm, renal hypertension or atherothrombot-
ic event. It may be worth noting that cardiovascular
risk factors were less predictive of PAD than mea-
surements of arterial blood pressure or LDL choles-
terol.
A large number of general practitioners (over
1200) and patients (nearly 6000), well-distributed
throughout the territory, participated in the study.
Overall, the results are consistent with those of the
other large studies in the primary care setting. Preva-
lence of PAD has been evaluated using the ABI at
Cerebrovascular 
disease 
n = 297  
Coronary artery 
disease 
n = 1340 
Peripheral arterial 
disease 
n = 362   
24.6% 
(19.8 to 29.9)  
26.6% 
(24.3 to 29.1)  
31.1% 
(23.4 to 39.6) 
n = 135  
57.1% 
(42.2 to 71.2) 
n = 49   
60.0% 
(40.6 to 77.3) 
n = 30   
75.0% 
(68.0 to 81.1) 
n = 180   
70.7%
(65.7 to 75.4) 
Figure 2 Prevalence (95% conﬁdence interval) of peripheral arterial disease (ankle-brachial index < 0.90) in the subgroup
of patients with one or more history of atherothrombotic event according to the localization of the event (n = 2393)
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(28), Germany (29) and the Netherlands (20) and at
27–29% in patients with selected vascular risk factors
in France (23) and North America (22).
To our knowledge, this was the ﬁrst prevalence
study that took into account all types of high-risk
proﬁles. This allowed deep exploration of the preva-
lence of PAD and of predictive factors. In particular,
although combining history and laboratory values,
the cardiovascular risk factors were well character-
ised, including modiﬁable and unmodiﬁable vari-
ables. Cardiovascular treatments were, however, not
recorded in the study, rendering difﬁcult any analysis
of the modiﬁable risk factors in the population (i.e.
hypertension, hypercholesterolemia and diabetes)
and the possible impact on ABI measurement.
Besides, the well-known poor sensitivity of clinical
examination to diagnose PAD may have underesti-
mated the results in patients in two subgroups, those
with signs or symptoms suggestive of PAD and those
with history of established symptomatic PAD.
In this observational study, diagnosis of PAD was
based mainly on the ABI measurement, which is the
recommended standard for diagnosis (1). As much
as one primary prevention patient out of 10, and
one secondary prevention patient out of four, had an
ABI below 0.9. Systematic ABI measurement should
be performed in order that none of the patients with
atypical symptoms and none of those who are
asymptomatic, but who are at high risk suffer loss of
opportunity. Obviously diagnosis of PAD can be per-
formed by general practitioners. ABI measurement is
easily performed, not excessively time-consuming
and inexpensive. Further investigations or invasive
procedures are reserved for a small minority of
patients. Much of the ‘best medical treatment’ can
also be implemented in the primary care (30).
However, there is still under diagnosis of PAD and
insufﬁcient management of patients with PAD in pri-
mary care, in France (31) as in other developed
countries (1). Given the very high prevalence of PAD
we found in high-risk patients and the cardiovascular
morbidity and mortality associated with PAD (2,3),
undoubtedly better public and health professional
awareness would help preserve individual cardiovas-
cular health and achieve public health goals.
Acknowledgements
The authors wish to thank all general practitioners
who participated in the study. They are grateful to
M.H. Barlet (Winner Pharma, France) who helped
in ﬁeld monitoring; F. Bugnard (Mapi-Naxis,
France) and N. Schmidely (Bristol-Myers Squibb,
France) who helped analyse the data and
Dr M. Varastet (ClinSearch, France) who drafted
the manuscript.
Ethics
According to the French law, approval from an Eth-
ics Committee was not required (survey).
Table 3 Independent risk factors for peripheral arterial disease in patients of the cohort excluding those with
previously established symptomatic peripheral arterial disease (n = 5125). Multivariate logistic regression analysis
Variable vs. reference Odds ratio (95% CI) p-value
Age vs. (55–64) years
(64–74) years 1.21 (1.00–1.45) < 0.05
74 years or older 1.44 (1.18–1.75) < 0.001
Sign or symptom suggestive of PAD vs. absent
Intermittent claudication 3.73 (3.00–4.63) < 0.0001
Other leg pain while walking 1.69 (1.42–2.00) < 0.0001
Pulseless dorsalis pedis artery 2.86 (2.40–3.42) < 0.0001
Pulseless tibial artery 1.95 (1.61–2.37) < 0.0001
Cardiovascular risk factor vs. absent
Currently smoking 1.98 (1.62–2.43) < 0.0001
Formerly smoking (cessation > 1 year) 1.38 (1.15–1.66) < 0.001
Formerly smoking (cessation £ 1 year) 2.48 (1.79–3.42) < 0.0001
Diabetes 1.24 (1.06–1.44) < 0.01
LDL ‡ 3.3 mmol⁄l* 1.81 (1.23–2.66) < 0.01
History of atherothrombotic event vs. absent
Renovascular hypertension 2.21 (1.17–4.17) < 0.05
Angina pectoris⁄coronary artery angioplasty or bypass grafting 1.42 (1.21–1.67) < 0.0001
*Value at the latest measurement. PAD, peripheral arterial disease; CI, conﬁdence interval.
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